A prospective study to know the efficacy of short-term use of injectable depot medroxy progesterone acetate for contraception in tertiary care hospital from North West Rajasthan, India

Authors

  • Swati Kochar Department of Obstetrics and Gynecology, S. P. Medical College and A. G. H. Bikaner, Rajasthan, India
  • Arun Kumar Department of Obstetrics and Gynecology, S. P. Medical College and A. G. H. Bikaner, Rajasthan, India
  • Ankur Nama Department of Obstetrics and Gynecology, S. P. Medical College and A. G. H. Bikaner, Rajasthan, India
  • Neha Suthar Department of Obstetrics and Gynecology, S. P. Medical College and A. G. H. Bikaner, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20202333

Keywords:

Depot medroxy progesterone acetate, Irregular bleeding, Postpartum period

Abstract

Background: Population explosion is a major issue especially in our country with the second largest population in world next only to china starting the use of contraception in postpartum period is an effective method of increasing the gap between two pregnancies and hence reducing the family size. Objective was to study the efficacy of DMPA injection in postpartum period for contraception.

Methods: The study was a prospective study conducted on 100 patients during June 2018 to May 2019 in the department of obstetrics and gynaecology, S. P. Medical College Associate A. G. H., Bikaner, Rajasthan, India.

Results: In present study mild irregular bleeding was present in 21, 35 and 38 cases at initial visit, at 3 months and at 6 months follow up respectively. Moderate irregular bleeding was present in 8 cases at initial visit, 27 cases at 3 months and 18 cases at 6 months follow up while 37 and 43 cases had severe irregular bleeding at 3 and 6 months follow up respectively. At baseline, 89 and 10 and 1 cases had their blood sugar <100, 100-120 and >120 respectively, at 3 months follow-up, 94, 6 and 0 cases had their blood sugar level <100, 100-120 and >120 respectively while at 6 months follow-up 97, 3 and 1 cases had their blood sugar level <100, 100-200 and >200 respectively.

Conclusions: Injection DMPA use in postpartum period is safe, effective and reversible method with no deleterious metabolic effects and do not need special training to administer to it, so it is a good option of contraception for women who are lactating.

 

References

Huang YM, Merkatz R, Kang JZ, Roberts K, Hu XY, Di Donate F, et al. Postpartum unintended pregnancy and contraception practice among rural to urban migrant women in Shanghai. Contracept. 2012;86(6):731-8.

Westhoff C. Depot medroxyprogesterone acetate injection Depo Provera: a highly effective contraceptive option with proven long-term safety. Contracept. 2003;68(2):75-87.

Malarcher S, Meirik O, Lebetkin E, Shah I, Spieler J, Stanback J. et al. Provision of DMPA by community health workers: what the evidence shows. Contracept. 2011;83(6):495-503.

Fonseca M, Deshmukh PY, Kharat D. DMPA: Acceptance and compliance in a tertiary care hospital in Mumbai. Int J Reprod Cntracept Obstet Gynecol. 2017;6(9):3879-81.

Rani S. A study on injectable DMPA (Depomedroxy progesterone acetale) isomg use as short-term contraception in immediate postpartum women. Int J Med Helth Res. 2017;3(9):17-22.

Mishra S, Gupta R. Acceptability and compliance of DMPA among rural women in Sitapur UP. Int J Clin Obstet Gynecol. 2019;3(2):8-10.

Khadilkar SS. Short term use of injectable contraception: An effective strategy for safe motherhood. J Obstet Gynecol Ind. 2018;68(2):82-7.

Downloads

Published

2020-05-27

Issue

Section

Original Research Articles